China's NMPA accepts Hengrui's ribupatide filing for type 2 diabetes
China's drug regulator has begun formal review of ribupatide, a weekly dual GLP-1/GIP shot from Hengrui, whose partner Kailera is running late-stage obesity trials that could eventually reach the US.
China's National Medical Products Administration has accepted Jiangsu Hengrui Pharmaceuticals' new drug application for ribupatide injection, a dual GLP-1/GIP receptor agonist, for blood sugar control in adults with type 2 diabetes [1]. The acceptance, announced September 9, 2026, means the filing is now in formal technical review; Hengrui did not disclose an expected approval date [1].
Ribupatide is known as HRS9531 in China and KAI-9531 outside Greater China [1]. It is classified as a Class 1 innovative drug, meaning it was developed in-house rather than licensed in [1]. The molecule activates both the GLP-1 and GIP receptors, an approach designed to combine glucose-dependent insulin release, suppression of glucagon and appetite regulation [1]. Hengrui is developing it in two forms: a once-weekly injection under the skin and a once-daily oral tablet [1].
If cleared, it would be the first dual GLP-1/GIP agonist developed in China to reach the market there, giving Chinese payers a domestic alternative to imported dual agonists [1]. The best-known drug in that class in the US is tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity and sleep apnea.
What the filing does and does not show
Hengrui's announcement did not release trial readouts, effect sizes or head-to-head comparisons against marketed incretin drugs [1]. That means the specific A1C and weight numbers behind the Chinese diabetes filing are not yet public. Pricing and reimbursement plans were also not disclosed [1]. The company's own forward-looking statement notes that acceptance of a filing does not guarantee eventual approval [1].
The broader China program for ribupatide covers weight management in adults and adolescents, type 2 diabetes, obstructive sleep apnea with obesity, metabolic dysfunction-associated steatohepatitis (MASH), reduction of major adverse cardiovascular events in people with atherosclerotic cardiovascular disease, and obesity with knee osteoarthritis [1]. That spread mirrors how the whole incretin class is being tested across cardiometabolic conditions [1].
The US connection
In May 2024, Hengrui granted Kailera Therapeutics exclusive rights to develop, manufacture and commercialize its GLP-1 portfolio, including ribupatide, outside Greater China [1]. Kailera is running the global Phase 3 KaiNETIC trial of ribupatide injection in obesity and plans to start a global Phase 3 of the oral version in obesity in the first half of 2027 [1].
So the Chinese diabetes filing does not directly move a US application forward. No US Food and Drug Administration submission date for ribupatide is stated in the available sources, and whether or when one will be filed is not yet known.
Ribupatide is not Hengrui's only late-stage metabolic candidate. A separate molecule, the oral small-molecule GLP-1 agonist HRS-7535 (safiglipron, called KAI-7535 outside China), was accepted for review in China on the reported date of September 3, 2026, for long-term weight management in adults with a BMI of 28 or above, or 24 or above with at least one weight-related condition [2]. That filing followed the Phase 3 HARBOR-1 trial, in which 556 adults at 50 centers in China took 120 mg or 180 mg once daily or placebo, with all dose groups meeting the primary and key secondary endpoints at 44 weeks [2].
Why it matters for patients
For Americans taking or considering GLP-1 drugs, nothing changes today. Ribupatide is not approved anywhere, and this filing applies only to China [1]. Its practical significance is about the future shape of the market: a second dual GLP-1/GIP agonist advancing through late-stage testing adds a potential competitor to the drugs now available, and more competing options in a drug class have historically been the main path to broader supply and price pressure. Whether that happens here depends on trial results and regulatory decisions that have not occurred.
The oral versions are worth watching for people who would rather not inject. But no efficacy or safety numbers for oral ribupatide in obesity have been released, and the global study has not started [1].
What happens next
- Now: NMPA technical review of the ribupatide injection filing is underway; no approval timeline disclosed [1].
- Ongoing: Kailera's global Phase 3 KaiNETIC trial of ribupatide injection in obesity [1].
- First half of 2027: Kailera plans to begin a global Phase 3 trial of oral ribupatide in obesity [1].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.